Effectiveness of a Hybrid Cardiac Rehabilitation Program: A Pragmatic Randomized Controlled Trial.

J Cardiopulm Rehabil PrevMar 17, 2026 (epub)
Clinical ResearchCardiology

Pamela Tanguay, Nicole Marquis, Monique Dufour Doiron et al.

✦ AI-curated · Sources linked

In 30 seconds

This nine-centre pragmatic randomised controlled trial compared hybrid with traditional cardiac rehabilitation in participants enrolled in cardiac rehabilitation. Traditional rehabilitation provided in-centre exercise twice weekly for 12 weeks; the hybrid program shifted from six weeks of in-centre sessions to progressively more home-based sessions over the next six weeks. Among 295 participants recruited, 224 completed the end-of-program assessment (76%) and 169 were assessed at six months (57%). Most outcomes did not differ significantly between groups. Both groups improved across all measured outcomes by program completion, and benefits were maintained at six months.

Key findings

  • Of 295 participants recruited, 224 completed the end-of-program assessment (76%) and 169 were followed up at six months (57%).
  • There were no statistically significant between-group differences for physical activity, functional capacity, anxiety, or depression; HRQoL was the exception.
  • Both groups improved significantly in all measured variables between baseline and program completion.
  • At six months, no significant changes or between-group differences were found, consistent with maintenance of benefits.

Why it matters

The findings suggest that a hybrid delivery model can achieve improvements similar to traditional in-centre cardiac rehabilitation across most measured outcomes, with benefits maintained at six months. This is relevant when considering rehabilitation delivery options, while the HRQoL difference and substantial loss to follow-up warrant attention when interpreting comparative effectiveness.

What to keep in mind

Follow-up completion was limited: 76% completed the end-of-program assessment and 57% were assessed at six months. The abstract does not report the direction or magnitude of the HRQoL difference.

Source

Published in J Cardiopulm Rehabil Prev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.